Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$1.26 - $2.71
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $47.40M |
EV | $30.80M |
Shares Outstanding | 29.86M |
Beta | 0.29 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $7.00 |
P/E 2025E | - |
P/Revenue 2025E | 14.60x |
Revenue | - |
EPS | 51.50% |
Operating Cash Flow | -109.40% |
Free Cash Flow | -54.60% |
Revenue | - |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -145.76% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Immix Biopharma, Inc.
IMMX
Sector
Healthcare
Industry
Biotechnology
CEO
Rachman, Ilya
Employees
20
Website
www.immixbio.comIPO Date
2021-12-16
Headquarters
11400 West Olympic Boulevard, Suite 200, Los Angeles, California, 90064, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved